<DOC>
	<DOCNO>NCT02413359</DOCNO>
	<brief_summary>The patient complication COPD asthma feature mixed two disease , COPD asthma . Therefore , outcome worsen patient COPD symptom overlap asthma , however , sufficient data exist Japan estimate prevalence ACOS patient COPD . The primary objective NIS clarify proportion ACOS define GINA GOLD patient COPD . The main secondary objective To explore feature history COPD exacerbation , symptom , eosinophilic inflammation patient background patient ACOS , clarify history COPD exacerbations patient COPD , evaluate degree eosinophilic inflammation respiratory tract patient COPD evaluate symptom patient COPD . This cross-sectional study target COPD patient receive outpatient treatment follow-up physician Japan . FSI schedule 2Q 2015 DBL would lock 3Q 2015 .</brief_summary>
	<brief_title>High Risk Populations Among COPD Patients Japan</brief_title>
	<detailed_description>Study Site ( ) , number subject plan Number study site plan research study ( schedule ) 60 ( undetermined ) Number subject plan research study ( schedule ) 1,100 patient</detailed_description>
	<criteria>Inclusion criterion Patients diagnosis COPD ( FEV1/FVC &lt; 0.7 confirmed base past medical record ) Patients age 40 year diagnosis COPD Outpatient 10 packyears current former smoker Patients traceable medical record COPD ( include result spirometry ) go back year Patients meet follow two criterion 1 . Patients medical record result spirometry two different time point exclude time point COPD exacerbations* past 3 year 2 . Patients provide result reversibility test respiratory tract Patients give write informed consent regard participation study Exclusion criterion Patients currently COPD exacerbation Patients currently enroll interventional study include clinical trial Patients concurrently develop history lung cancer Patients disable understand study procedure answer questionnaire ( i.e . due history alcohol drug abuse )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>